IONS · NASDAQ · STOCK
Ionis Pharmaceuticals (IONS) Stock Analysis
$45.26
52W $42.63 – $86.74
44/100
$7.52B
-13.1
0.38
Is IONS Bullish or Bearish?
Mixed.
Innellis AI committee rates Ionis Pharmaceuticals, Inc. (IONS) Reduce with a composite score of 44/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Watch
- Requires a committee score of 45.0 — +0.66 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Sell
- Requires the score to fall below 25.0 — -19.34 from today. The band boundary is 30.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.25 across 8 articles, 14d). Growth Analyst remains cautious — revenue declining -7.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- News sentiment is positive (+0.25 across 8 articles, 14d) — News
Bear Case
- Price-to-book of 26.2x prices in significant intangible value — Value
- ROE of only -110.9% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 4.77 adds balance-sheet risk to the value case — Value
- Revenue declining -7.5% YoY -- this is not a growth story right now — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- Price structure making lower highs and lower lows — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
44/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 99%
of 192 Healthcare peers
Value Analyst
bearish
32
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 26.2x prices in significant intangible value
Growth Analyst
bearish
25
/ 100 · Moderate confidence
Growth story is weak, decelerating, or inconsistent
− Revenue declining -7.5% YoY -- this is not a growth story right now
Technical Analyst
neutral
46
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− Price structure making lower highs and lower lows
Risk Analyst
bearish
32
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 4.77) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.25 across 8 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 43.8 to 44.3.
- New bearish signals: 1 appeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- News Analyst: score 62->66 (+3); +1 bullish signal(s).
- Risk Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
50.4
Neutral
MACD Histogram
0.440
Bullish Momentum
Trend Direction
Downtrend
Weekly: Uptrend
Market Structure
Lh Ll
Support
$40.14
Resistance
$45.51
Bollinger %B
0.53
Inside Bands
Price vs Moving Averages
EMA 9
$44.46
Above
EMA 21
$46.63
Below
EMA 50
$52.02
Below
EMA 200
$62.39
Below
Fundamental Analysis
Valuation
67
Growth
64
Profitability
25
Financial Health
50
Cash Flow
15
Valuation
P/E Ratio
-13.1×
P/B Ratio
17.03×
PEG Ratio
0.16
Dividend Yield
0.00%
52W High
$86.74
52W Low
$42.63
Quality & Growth
ROE
-7790.0%
ROA
-1081.2%
Gross Margin
9816.2%
Operating Margin
-6808.5%
Revenue Growth YoY
—
Debt / Equity
5.50
AI Fundamental Assessment
P/E ratio of -13.1 (inexpensive relative to a 15-40x range); Price-to-book of 17.0x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -77.9%; Return on assets of -10.8%; Net margin of -64.6%; Gross margin of 98.2%; Current ratio of 7.88 (healthy short-term liquidity); Debt-to-equity of 5.50; Free cash flow per share is negative (-3.38); Most recent quarter beat estimates by 36.7%; 2 consecutive earnings beats; EPS growth decelerating (+60.3% -> -23.2% QoQ); Analyst estimates rising over recent quarters
Get the Full IONS Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →